Recommendations for good clinical practice for DPD bone scintigraphy for cardiac amyloidosis.

Autor: Wechalekar, Kshama, Hutt, David, Quigley, Ann Marie, Whelan, Carol, Pei San Chan, Hossen, Lucy, Armstrong, Ian, Arumugam, Parthiban, Moody, William, Wechalekar, Ashutosh D.

Publikováno v: Nuclear Medicine Communications; Apr2024, Vol. 45 Issue 4, p253-262, 10p

Autologous Stem Cell Transplantation in AL-Amyloidosis Following Yttrium-90 Labelled Anti-CD66 Monoclonal Antibody As Sole Conditioning Is Associated with Low Toxicity and Demonstrable Disease Responses

Autor: Paul Lloyd-Evans, Kim Orchard, Matthew Guy, Denise A. Phillips, Pei-San Chan, Caspar Wickham, Claire Hutchison, Gemma Lewis, Jon Langford, Sofia Michopoulou, Clint Zvavamwe, Mark J. Cook, Julian Williams, Ashutosh D. Wechalekar, Ann-Marie Quigley, Graham Jackson, Philip N. Hawkins, Jane Nunnick, Amanda Blackwell

Publikováno v: Blood. 138:3819-3819

Delayed diagnosis and lack of effective therapies results in the death of approximately 30% of patients with AL-amyloidosis (AL-A) within the first year of diagnosis. Autologous stem cell transplantation (ASCT) remains an important treatment option,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2c17566325ce7f08ddad254c55bc1e8
https://doi.org/10.1182/blood-2021-146300

Safety, tolerability and clinical implementation of ‘ready-to-use’ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Autor: Prakash Manoharan, Martyn Caplin, Shaunak Navalkissoor, Pei San Chan, Angela Lamarca, Peter J Julyan, Juan W. Valle, Maribel Lopera Sierra, Jose Calero

Publikováno v: Manoharan, P, Lamarca, A, Navalkissoor, S, Calero, J, Chan, P S, Julyan, P J, Sierra, M L, Caplin, M & Valle, J 2020, ' Safety, tolerability and clinical implementation of 'ready-to-use ' (68)gallium-DOTA0-Tyr3-octreotide (Ga-68-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) ', ESMO Open, vol. 5, no. 2, e000650 . https://doi.org/10.1136/esmoopen-2019-000650

Background: 68Ga-DOTA0-Tyr3-octreotide ( 68Ga-DOTATOC) positron emission tomography-CT (PET-CT) has superior diagnostic performance compared to the licensed tracer OctreoScan single photon emission CT-CT in patients with gastroenteropancreatic neuroe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a05d7e5ef36b95003873642ec3f29c97
https://doi.org/10.1136/esmoopen-2019-000650

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas

Autor: Anwar R. Padhani, R. Barbara Pedley, Karen Owen, N. Jane Taylor, Andrew M. Gaya, Richard H. J. Begent, John Violet, Lisa K. Folkes, Kerry A. Chester, Pei-San Chan, Gordon J. S. Rustin, Shokri Othman, David Wellsted, Linda Poupard, Michael R.L. Stratford, Tim Meyer, Gairin Dancey, J. James Stirling, Alan J. Green, Alessandra Malaroda, Surinder K. Sharma, John R. Buscombe

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 15(13)

Purpose: In preclinical models, radioimmunotherapy with 131I-A5B7 anti–carcinoembryonic antigen (CEA) antibody (131I-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone. We c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcbbc36929b7b3b91bacfe3e8154b7b7
http://ora.ox.ac.uk/objects/uuid:03bc90af-a61a-4d0e-8bd3-0374177a2972